


Val-Cit-amide-Ph-Maytansine

Cat. No.:	HY-156897		
Molecular Formula:	C ₅₁ H ₇₁ ClN ₈ O ₁₄		
Molecular Weight:	1055.61		
Target:	Drug-Linker Conjugates for ADC		
Pathway:	Antibody-drug Conjugate/ADC Related		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (94.73 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		0.9473 mL	4.7366 mL	9.4732 mL
		5 mM		0.1895 mL	0.9473 mL	1.8946 mL
10 mM		0.0947 mL	0.4737 mL	0.9473 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.37 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.37 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.37 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) ^[1] .
--------------------	--

REFERENCES

[1]. Schwartz, Gary, et al. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind Met. World Intellectual Property Organization, WO2020172475 A1 2020-08-27

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA